{
  "abstract": "Lai et al proposed pragmatic non-invasive thresholds to select patients with metabolic dysfunction-associated steatotic liver disease (MASLD) for hepatocellular carcinoma (HCC) surveillance via fibrosis-4 index (FIB-4) and vibration-controlled transient elastography (VCTE)-derived liver stiffness measurement (LSM).1 To make the proposed thresholds workable as a repeatable pathway in routine care, we ask the authors to clarify three practical aspects.",
  "authors": [
    {
      "affiliations": [
        "Department of Laboratory Medicine, Shuyang Hospital of Traditional Chinese Medicine, Shuyang, China"
      ],
      "name": "Guang Wu"
    },
    {
      "affiliations": [
        "Laboratory Medicine, Shuyang Hospital, The Affiliated Shuyang Hospital of Xuzhou Medical University, Shuyang, Jiangsu, China"
      ],
      "name": "Guo-Ming Zhang"
    }
  ],
  "title": "Clarifying the decision rules and implementation boundaries for risk-based HCC surveillance in MASLD",
  "uid": "badd1616-6b2d-526a-a805-5c402e3d5922"
}